MAIA

Insider Trades

Name	Value	Action	Price	Current Price
Gryaznov SergeiChief Scientific Officer $2.7k2k shares BuyJun 1, 2026 $1.35 --
Smith StanDirector $100k75k shares BuyJun 1, 2026 $1.34 --
Vitoc VladDirector, 10 Percent Owner, Officer: Chief Executive Officer $101k72.7k shares BuyJun 1, 2026 $1.39 --
Louie Ngar YeeDirector $111k81.7k shares BuyDec 22, 2025 $1.36 --
Louie Ngar YeeDirector $100k81.7k shares BuyDec 22, 2025 $1.22 --
Smith StanDirector $78k57.2k shares BuyDec 22, 2025 $1.36 --

News

globenewswire.comMAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory Universityglobenewswire.comJun 18

globenewswire.comMAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trialglobenewswire.comJun 10

globenewswire.comMAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trialglobenewswire.comJun 4

Trade MAIA

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.

CEO: Vlad Vitoc
IPO Date: Jul 28, 2022

Market Data

Open: $1.32
High: $1.41
Low: $1.32
Volume: 477.5K
Avg Volume: 788.9K
52W High: $3.19
52W Low: $0.87

Valuation

Market Cap: $85M
Enterprise Value: $51M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-19M
Revenue: $0
Net Income: $-22M
Cash: $8.7B
Debt: $0

Events

EarningsAug 10

EPS est. -0.11